ReviewFrontiers in medicine2026
Bibliometric analysis of research on sarcopenia in rheumatoid arthritis: 1997-2025.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to utilize bibliometric techniques to examine the current state, emerging trends, research frontiers, and developmental trajectories in the field of sarcopenia in rheumatoid arthritis (RA). Methods: A comprehensive literature search was conducted in the Web of Science Core Collection (WoSCC; SCI-EXPANDED and SSCI) and Scopus databases for studies related to RA and sarcopenia from database inception to December 31, 2025. The search strategy used Boolean operators and field tags with the query: ("rheumatoid arthritis" OR "RA") AND ("sarcopenia" OR "muscle loss" OR "muscle mass" OR "muscle wasting" OR "skeletal muscle" OR "muscular atrophy"). Only articles and reviews published in English were included. Bibliometric analyses were performed using VOSviewer (version 1.6.20) and CiteSpace (version 6.4.R1) to generate visual representations of collaboration networks, keyword co-occurrence, cluster analysis, timeline mapping, and citation burst detection. Results: A total of 433 documents (476 from WoSCC and 527 from Scopus after deduplication and screening) were included. The annual publication output increased slowly from 1996 to 2007, steadily from 2008 to 2015, and exponentially from 2016 to 2025, with 61 articles published in 2025 alone. The United States ranked first in productivity (67 publications, 5,915 citations), followed by China (63 publications, 961 citations) and Japan (58 publications, 971 citations). Osaka City General Hospital was the most productive institution (20 publications). The journal Annals of the Rheumatic Diseases published the highest number of articles (66). Keyword co-occurrence analysis identified five major clusters: rheumatoid arthritis, sarcopenia, body composition, cachexia, and skeletal muscle. Timeline and burst detection revealed a clear evolution from descriptive body composition studies (1996-2005) to inflammatory mechanisms (2006-2014), then to epidemiological characterization and non-pharmacological interventions (2015-2020), and finally to diagnostic validation and precision-oriented research (2021-2025). Emerging frontiers include multi-omics approaches (e.g., gut microbiota, cuproptosis), machine learning-based risk prediction, and targeted biologic therapies. Conclusion: Over the past three decades, research on sarcopenia in rheumatoid arthritis has expanded substantially, with rapid growth in the last five years. The field has shifted from basic description to mechanistic understanding and clinical precision. The identified research hotspots and evolutionary trends provide a valuable roadmap for future investigations into the RA-sarcopenia axis, highlighting the need for standardized screening, multidisciplinary care, and innovative translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.